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UL9 is the origin binding protein of herpes simplex virus type-1 (HSV-1). A UL9-specific monoclonal antibody (17B) whose
epitope maps to the N-terminal 33 amino acids was used to study the localization of UL9 in infected and transfected cells.
We demonstrate the colocalization of UL9 and the HSV-1 single-strand DNA binding protein (ICP8 or UL29) in replication
compartments, sites of viral DNA synthesis. On the other hand, UL9 does not completely colocalize with ICP8 in prereplicative
sites, structures observed under conditions that inhibit viral DNA polymerase. Cells transfected with various deletion or
pyruvate kinase fusion constructs were analyzed by indirect immunofluorescence assay to define the nuclear localization
signal (NLS) of UL9. Deletion analysis showed that the region required for nuclear localization lies within the C-terminal
DNA binding domian (amino acids 535– 851). Various regions of UL9 were tested in fusion constructs for their ability to
direct the normally cytoplasmic chicken pyruvate kinase protein to the nucleus. A fusion construct containing the carboxy-
terminal 107 residues (amino acids 745– 851) localized efficiently to the nucleus, whereas a fusion construct containing the
N-terminal 660 amino acids of UL9 was unable to do so. Mutations designed to alter a potential NLS sequence (793-
KREFAGARFKLR-804) within the C-terminal 107 residues result in a mutant UL9 protein which fails to localize efficiently to
the nucleus. These results suggest that the major NLS of UL9 maps within the C-terminal 107 amino acids. q 1996 Academic
Press, Inc.
INTRODUCTION recombinant HSV-1 virus which overexpresses UL9 and
the immediate-early gene products (Calder et al., 1992).
Herpes simplex virus type-1 (HSV-1) is the prototype Thus UL9 contains a nuclear localization signal (NLS);
virus for the Alphaherpesviridae subfamily of double- however, its location within the protein has not been
stranded DNA viruses. HSV-1 has three origins of replica- mapped.
tion, and initiation presumably requires the virally en- HSV-1 replication occurs in specific regions in the nu-
coded origin binding protein, UL9 [see review (Weller, cleus called replication compartments (Quinlan et al.,
1995)]. UL9 exhibits helicase and ATPase activities in 1984; Rixon et al., 1983). These were immunologically
vitro, forms dimers in solution, and cooperatively binds defined based on the globular staining patterns of the
origin-specific DNA (Bruckner et al., 1991; Elias et al., HSV-1 single-strand DNA binding protein (ICP8 or UL29)
1992; Fierer and Challberg, 1992; Hazuda et al., 1992). in infected cell nuclei (de Bruyn Kops and Knipe, 1988;
The helicase and ATPase functions are presumably en- Quinlan et al., 1984). Indirect immunofluorescence exper-
coded by the N-terminal two-thirds (residues 1– 534) of iments have shown that other HSV-1 replication proteins
UL9 which contain helicase consensus motifs (Abbotts including the heterodimeric HSV-1 DNA polymerase
and Stow, 1995; Martinez et al., 1992). The DNA binding (UL30 and UL42) and the heterotrimeric HSV-1 helicase–
domain has been mapped to the C-terminal third of UL9 primase (UL5, UL8, and UL52) colocalize with ICP8 in
(residues 535 – 851) (Arbuckle and Stow, 1993; Deb and replication compartments (Bush et al., 1991; Goodrich et
Deb, 1991). Interactions of UL9 with other viral and cellu- al., 1990; Liptak et al., 1996; Lukonis and Weller, 1996).
lar replication proteins have been described including Several cellular proteins including DNA polymerase a,
ICP8, the HSV-1 single-strand DNA binding protein cellular single-strand DNA binding protein (RP-A), PCNA,
(Boehmer et al., 1994; Boehmer and Lehman, 1993); UL8, p53, Rb, DNA ligase, and topoisomerase II also redistrib-
a member of the HSV-1 helicase– primase complex ute to these compartments in infected cells (Ebert et al.,
(McLean et al., 1994); and the catalytic subunit of the 1994; Wilcock and Lane, 1991). Previous studies by Olivo
cellular DNA polymerase a-primase (Lee et al., 1995). et al. demonstrated that an anti-UL9 rabbit antiserum
UL9 localizes to the nucleus in cells transfected with a recognizes globular structures in infected cell nuclei rem-
UL9 expression clone (Malik et al., 1992) or infected with iniscent of replication compartments (Olivo et al., 1989).
In this report we have characterized and used a UL9-
specific mouse monoclonal antibody, 17B, to confirm and1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (860) 679-1239; E-mail: weller@panda.uchc.edu. extend the observations that UL9 localizes to the replica-
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tion compartments and to determine the nuclear localiza- residue. Other deletions, D1-35, D1-534, and D13-536
are described elsewhere (Malik and Weller, 1996).tion signal of UL9.
The chicken pyruvate kinase fusion plasmids were
constructed by using the pyruvate kinase (PK) cassetteMATERIALS AND METHODS
vectors (Gao and Knipe, 1992). The plasmid pN98-PK
Cells and viruses was constructed by digesting p6UL9-1i at the unique
Not I site in the UL9 gene and the EcoRI site in the poly-Vero cells (African green monkey kidney cell line ob-
linker. The 3.9-kb fragment containing the vector back-tained from ATCC) were maintained in tissue culture as
bone, the ICP6 promoter, and the N-terminal 98 aminopreviously described (Weller et al., 1983). HSV-1 strain
acids of UL9 was isolated and the overhanging endsKOS was the wild-type virus. The hr94 and hr114 viruses
were treated with Klenow. The PK gene was isolated oncontain a lacZ insertion in the UL9 or UL52 genes, re-
a 1.8-kb Bgl II fragment from pPK12 (Gao and Knipe,spectively (Goldstein and Weller, 1988; Malik et al., 1992).
1992), the ends were treated with Klenow, and the PK
fragment was ligated in frame with the 3.9-kb p6UL9-1iPlasmids
fragment (above). Using a similar strategy, pN196-PK and
pN292-PK were constructed from p6UL9-2i and p6UL9-The pVP16-9 plasmid which expresses the HSV-1
transactivator, VP16, from the MSVLTR promoter cloned 3i, respectively, and the PK gene from pPK12. pN33-PK
was also constructed using a similar strategy by ligatinginto pTZ19R, was kindly provided by Dr. S. Weinheimer
(Bristol-Myers Squibb, Wallingford, CT). p6UL5, p6UL8, the PK cassette from pPK10 between the unique NheI
site in the UL9 gene and EcoRI site in p6UL9-119b.and p6UL52KT3 containing UL5, UL8, and KT3 epitope-
tagged UL52 expressed from the inducible ICP6 pro- pN535-PK was constructed by inserting the PK gene on
a 1.8-kb Bgl II fragment of pPK12 at the unique BamHImoter were previously described (Lukonis and Weller,
1996). p6UL9-119b contains the UL9 gene expressed site within the UL9 gene in p6UL9-119b. pN660-PK was
constructed from pN292-PK by replacing the 0.8-kbfrom the inducible ICP6 promoter (Malik et al., 1992).
A series of UL9 plasmids (p6UL9-1i to -8i) containing NheI– EagI fragment containing amino acid residues 34–
292 of UL9 with the 1.8-kb NheI– EagI fragment of p6UL9-Ala-Ala insertion mutations (i97, i195, i291, i404, i520,
i597, i703, and i798, respectively) that result in the intro- 119b containing amino acids 34 – 660. pN33-PK– C107
containing amino acid residues 1– 33 and 745– 851 ofduction of a unique Not I site were described earlier (Mar-
tinez et al., 1992). These plasmids facilitated the con- UL9 fused to PK was constructed by ligating the 1.2-kb
Bgl II – StuI pyruvate kinase cassette from pPK10 be-struction of six internal deletions (D98-195, D196-291,
D292-404, D405-520, D521-597, and D598-703). For in- tween the NheI site at amino acid 33 and the MscI site
at amino acid 745 of UL9 in p6UL9-119b. The noncohe-stance, p6UL9-D98-195 was constructed by ligating the
NotI – EcoRI vector backbone fragment of p6UL9-1i which sive ends were treated with Klenow. Similarly, pN33-PK–
C107(D800-803) was constructed by inserting the py-contains the ICP6 promoter and the 5* end of the UL9
gene to the 2.2-kb Not I– EcoRI fragment of p6UL9-2i ruvate kinase cassette (Bgl II – StuI fragment) between the
NheI and the MscI sites of p6UL9-D800-803. The junc-which contains the 3* end of the gene; this results in the
deletion of the 98– 195 amino acid region of UL9. The tions of all plasmid clones were verified by dideoxy chain
termination sequencing method using Sequenase 2.0 asexpected protein will contain amino acids 1– 97 and two
alanines followed by amino acids 196– 851. recommended by the supplier (U.S. Biochemicals, Cleve-
land, OH).The p6UL9-D800-851 was constructed by introducing
an XbaI linker (5*-CTA-GTC-TAG-ACT-AG) at position 798
following linearization of p6UL9-8i with Not I and Klenow Generation of UL9-reactive monoclonal antibodies
treatment. The expected protein will contain amino acids
1– 799 of UL9 followed by Ala-Leu-Val amino acids. A 20-week-old female BALB/c mouse was immunized
with 10 mg of recombinant baculovirus purified UL9p6UL9-D800-803 was constructed from p6UL9-8i and
p6UL9-119b as follows: p6UL9-8i was digested with NotI [kindly provided by Drs. Dan Fierer and Mark Challberg,
NIH (Fierer and Challberg, 1992)] in 0.5 ml of completeand the ends were filled in by treatment with the Klenow
enzyme and further digested with NheI. The 2.3-kb NheI – Freund’s adjuvant (CFA). The booster injections was
given 10 weeks later (with 10 mg of UL9 in CFA) and 10NotI (blunt) fragment from within the UL9 gene was iso-
lated. Plasmid p6UL9-119b was digested with MluI, weeks thereafter (with 10 mg of UL9 in phosphate-buf-
fered saline). Three days after the last booster, the spleentreated with Klenow to fill in the ends, and digested with
NheI. The 4.3-kb NheI– MluI (blunt) fragment containing cells (5.8 1 107) were isolated and fused with NSO my-
eloma cells (1.361 107) in the presence of 50% polyethyl-the C-terminus of the UL9 gene, the vector backbone,
and the promoter was isolated and ligated to the 2.3-kb ene glycol. The fused cells were resuspended in 20 ml
of HAT medium and a 100-ml aliquot of the cell suspen-fragment from p6UL9-8i. The expected protein will con-
tain a replacement of residues 800– 803 with an alanine sion was transferred to each well of a 96-well plate and
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incubated in a 10% CO2 incubator. IgG production of For immunofluorescence analysis of the KOS- or hr94-
infected cells, a total of 2.51 105 Vero cells were seededthe hybridoma cells was screened by immuno-dot blot
analysis by pipeting 1-ml aliquots of the cell culture su- onto a 60-mm dish containing three to four round cov-
erslips. Cells were incubated overnight at 377 and in-pernatant onto nitrocellulose membrane and incubating
the membrane with the horseradish peroxidase-conju- fected with KOS or hr94 at a m.o.i. of 10 PFU/cell in the
presence or absence of 0.4 mg/ml phosphonoacetic acidgated goat anti-mouse antibody, using diaminobenzidine
as the color reagent (Harlow and Lane, 1988). A total of and 20 mM HEPES, pH 7.6. Six hours postinfection, the
cells were fixed in 3.7% formaldehyde in PBS, permeabil-39 IgG-positive clones were obtained from 200 clones
which were tested. The IgG-positive clones were ized in 1% Triton X-100, blocked in 3% NGS, and incu-
bated with a 1:50 dilution of 17B or 1:500 dilution ofscreened for reactivity to UL9 and 2 positive clones were
obtained. Both UL9-positive clones were subcloned in anti-KT3 ascites and a 1:1000 dilution of the 3-83 rabbit
antiserum [raised against ICP8; kindly provided by Dr.0.3% low melting agarose in DME and overlaid on plates
containing a 50% confluent monolayer of mouse fibro- David Knipe (Harvard) (de Bruyn Kops and Knipe, 1988;
Knipe et al., 1987)] The cells were then incubated withblasts (feeder cells). Colonies were picked and were fur-
ther subcloned. Two series of clones were obtained: 12- 1:200 dilutions of goat anti-rabbit Texas red conjugate
and goat anti-mouse fluorescein conjugate (Cappel6-7 and 17-4-2. One subclone of the 17 series, 17B, was
further characterized. Labs). Confocal images were collected on a Zeiss Axio-
vert laser scanning microscope.
Immunofluorescence assays (IFA)
Transient transfection – immunoblot assayThe wild-type and the mutant versions of UL9 were
expressed from the ICP6 promoter which can be induced A total of 1.5 1 106 Vero cells were transfected with 8
by cotransfection with either VP16 or ICP0 transactivator-
mg of the UL9 or mutant expression plasmid. Transfected
expressing plasmid (Malik et al., 1992). A total of 1 1 106 plasmids were induced by infecting the cells with the
Vero cells were transfected with 8 mg each of wild-type UL9 null virus, hr94, at 10 PFU/cell. The cells were pro-
or mutant versions of a UL9 expression plasmid and 1 mg cessed for total cell protein by acetone precipitation as
of plasmid expressing VP16 by the CaPO4 precipitation previously described (Malik and Weller, 1996). The ex-
method as described previously (Zhu and Weller, 1988). tracts were separated on an 8% SDS – PAGE gel and
After incubation for 24 hr at 377, transfected cells grown immunoblotted on Immobilon-P membrane (Millipore,
on coverslips were fixed in methanol:acetone (1:1), per- Bedford, MA). The immunoblots were incubated with a
meabilized with 1% Triton X-100, blocked in 3% normal 1:25 dilution of 17B monoclonal antibody or a 1:5000
goat serum (NGS), and stained with antibodies as de- dilution of anti-UL9 rabbit antiserum or a 1:5000 dilution
scribed (Malik and Weller, 1996). The 17B monoclonal of anti-pyruvate kinase rabbit antiserum. The secondary
antibody was used without any further dilution. Anti-py- antibodies were anti-mouse or anti-rabbit goat IgG-alka-
ruvate kinase rabbit antiserum, kindly provided by Dr. line phosphatase conjugate used at 1:5000 dilution (Pro-
David Knipe (Harvard, Boston, MA), was used at a 1:75 toblot system obtained from Promega, WI).
dilution (Gao and Knipe, 1992). The secondary antibodies
were used at a dilution of 1:200 (goat anti-mouse or anti- RESULTS AND DISCUSSION
rabbit rhodamine conjugate; Cappel Labs). The cells
were washed and mounted in glycerol– gelatin solution We isolated two mouse hybridoma clones, designated
12-6-7 and 17-4-2, expressing monoclonal antibodies re-containing 2.5% DABCO (1,4-diazabicyclo[2.2.2]octane).
In some experiments an avidin – biotin technique was active against recombinant baculovirus-expressed UL9.
One monoclonal antibody, 17B, from the 17 series wasused to enhance the sensitivity of the signal. In this case,
the transfected cells were fixed, permeabilized, and incu- further characterized. This antibody reacts with UL9 in
immunoblots [(Malik et al., 1992) and below] and IFA (seebated with 1:50 dilution of anti-UL9 rabbit antiserum
raised against the C-terminal decapeptide of UL9 [kindly below) and is capable of immunoprecipitating UL9 (data
not shown). The epitope of the 17B antibody was mappedprovided by Dr. Mark Challberg (NIH, Bethesda, MD)
(Olivo et al., 1988)] , as described above. The cells were using IFA. Vero cells were cotransfected with wild-type
or mutant forms of UL9 expressed from the ICP6 pro-incubated in a 1:200 dilution of horse anti-rabbit – biotin
conjugate in 3% NGS followed by a 1:200 dilution of fluo- moter and a VP16 plasmid to induce the expression of
UL9. Transfected cells were stained with the 17B anti-rescein-conjugated avidin in bicarbonate-buffered saline
(Vector Labs, CA). The cells were washed in bicarbonate- body or anti-UL9 C-terminal 10-amino-acid specific rabbit
antiserum. Cells transfected with VP16 alone did not re-buffered saline and mounted. Immunofluorescence im-
ages were collected on a Zeiss Axiovert 100TV micro- act with 17B or anti-UL9 rabbit antiserum (Figs. 1A and
1D). As shown in Fig. 1B, 17B stains the nuclei of cellsscope equipped with a Plan-Neofluar 631 1.25 NA oil
immersion lens and a CCD camera and controlled by the transfected with wild-type UL9. 17B does not react with
cells transfected with the D1-35 mutant which expressesInnovisions software program ISEE.
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FIG. 1. Monoclonal antibody 17B reacts with the N-terminal 33 amino acid residues of UL9. Vero cells were cotransfected with wild-type or
mutant UL9 and a VP16 expression clone as described under Materials and Methods. The cells were transfected with VP16 alone (A and D) or
cotransfected with VP16 and UL9 (B and E), D1-35 (F), or N33-PK (C) expression plasmids. The cells were stained with 17B mouse monoclonal
antibody (A – C) or anti-UL9 C-terminal-specific rabbit antiserum (D –F), followed by incubation with the goat anti-mouse or anti-rabbit antibody
conjugated to rhodamine. None of the antibodies used in IFA detected any staining of cells transfected with VP16 alone; the cells shown in A and
D are two representative cells chosen at random depicting background staining.
a truncated version of UL9 lacking the N-terminal 35 cell extracts were analyzed by immunoblotting using anti-
UL9 rabbit antiserum. As shown in Fig. 2A, wild-typeamino acids (data not shown). The D1-35 mutant could
be detected by the anti-UL9 rabbit antiserum (Fig. 1F). UL9 and six internal deletion mutants were expressed
as stable proteins of the expected sizes (lanes 1– 7). TheFurthermore, the 17B antibody reacted with the N33-PK
protein which contains the N-terminal 33 amino acids of C-terminal truncation mutant D800-851 was not detected
since the rabbit antiserum was specific for the C-terminalUL9 fused to the chicken pyruvate kinase (PK) gene (Fig.
1C). This construct localizes to the cytoplasmic compart- 10 amino acids of UL9 (data not shown). However, D800-
851 could be detected with the 17B monoclonal antibodyment as discussed below. These results indicate that the
epitope of the 17B monoclonal antibody lies within the (Fig. 2A, lane 9). Three other deletions which were stud-
ied here, D1-35, D1-534, and D13-536, also expressN-terminal 33 amino acids of UL9. We have used the
17B antibody to characterize the intracellular localization stable proteins (Malik and Weller, 1996).
The intracellular localization of the deletion mutantof UL9.
UL9 expressed from a CMV immediate-early promoter proteins in transfected cells was visualized by IFA as
described above. Figs. 2B– 2I show representative immu-in transfected cells localizes to the nucleus (data not
shown), suggesting that the nuclear import of UL9 does nofluorescence data from several deletion mutants. In
cells transfected with deletions D98-195, D196-291, andnot require any additional HSV-1 proteins and that the
protein may contain a nuclear localization signal. To de- D800-851, UL9 was predominantly cytoplasmic (Figs. 2B,
2C, and 2H, respectively). In the majority of cells trans-fine the protein sequence(s) essential for nuclear local-
ization, we constructed several deletion mutants of UL9 fected with deletion D521-597, staining is observed in
both the nucleus and the cytoplasm (Fig. 2F). These re-in an expression clone under the control of the inducible
ICP6 promoter. The ability of the deletion constructs to sults suggest that at least two regions of UL9 containing
amino acids 98 – 291 and 800 – 851 and perhaps a thirdexpress proteins of the expected size was determined by
a transient transfection-immunoblot assay as described containing amino acids 521– 597 may be important for
efficient nuclear localization. However, two UL9 dele-under Materials and Methods. Vero cells were trans-
fected with plasmids expressing either the wild-type or tions, D13-536 and D1-534, expressing the C-terminal
DNA binding domain with or without the N-terminal 12the mutant versions of UL9 from the ICP6 promoter which
can be induced by infection with hr94, the UL9 null virus amino acids localized efficiently to the nucleus (Figs. 2I
and 4E). This result suggests that the C-terminal 535- to(Malik et al., 1992). The transfected and hr94-infected
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FIG. 2. Characterization of the deletion mutants of UL9. (A) Immunoblot of extracts from cells transfected with wild-type or mutant versions of
UL9. Vero cells were transfected with the indicated plasmid, and protein expression was induced by infection with the hr94 virus as described
under Materials and Methods. The expressed proteins were resolved by SDS – PAGE and analyzed by immunoblotting. The UL9 mutants were
detected using anti-UL9 C-terminal-specific rabbit antiserum (lanes 1– 7) or the 17B monoclonal antibody (lanes 8 and 9). The UL9 mutants are
indicated on the top and the position of molecular weight markers (kDa) is shown on the left. (B– I) Intracellular localization of several deletion
mutants. Vero cells were cotransfected with the plasmids expressing mutant versions of UL9 and VP16 transactivator. The transfected cells were
stained with the 17B monoclonal antibody and a rhodamine-conjugated anti-mouse antibody. The cells were transfected with D98-195 (B), D196-
291 (C), D292-404 (D), D405-520 (E), D521-597 (F), D598-703 (G), D800-851 (H), and D1-534 (I) expression plasmids.
851-amino-acid region may contain an NLS. The failure N535-PK expressed stable proteins in a transient transfec-
tion– immunoblot assay. N660-PK also expressed stableof other N-terminal deletions to localize to the nucleus
may be a consequence of improper folding which may protein (data not shown). The ability of the fusion proteins
to localize to the nucleus was determined by IFA. Repre-result in the formation of insoluble aggregates or mask-
ing of the major NLS. Precedent for conformational sentative immunofluorescence data from these experi-
ments are shown in Figs. 3B– 3D. All six N-terminal PKchanges that modulate nuclear localization exists in the
behavior of heat shock factor 2 (Sheldon and Kingston, fusions (N33-PK, N98-PK, N196-PK, N292-PK, N535-PK, and
N660-PK) failed to localize to the nucleus. These results1993). Heat shock factor 2 contains two coiled-coil motifs
which interact to sterically block the NLS. Disruption of confirm that the putative NLS of UL9 is not present in the
N-terminal 660 amino acids of the protein. A PK fusion,this interaction during activation unmasks the NLS se-
quence (Sheldon and Kingston, 1993). N33-PK– C107, containing the C-terminal 107 amino acids
(residues 745–851) of UL9 in addition to the N-terminal 33To confirm that the NLS of UL9 lies within the C-terminal
535– 851 residues and determine if this region is also suffi- amino acids of UL9, was also constructed. N33-PK– C107
expressed a stable protein in transient transfection –immu-cient for nuclear transport, we constructed several in-frame
fusions containing sequences of UL9 fused to a heterolo- noblot assay (Fig. 3A, lanes 6). The results of IFA indicate
that N33-PK –C107 localizes to the nuclei of transfectedgous cytoplasmic protein, chicken PK. Six fusions con-
tained the N-terminal 33, 98, 196, 292, 535, or 660 amino cells (Fig. 3E). The ability of the N33-PK– C107 fusion to
localize to the nucleus indicates that the NLS of UL9 likelyacids of UL9 fused to pyruvate kinase. As shown in Fig.
3A (lanes 1– 5), N33-PK, N98-PK, N196-PK, N292-PK, and maps within the C-terminal 107 amino acids of UL9. The
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FIG. 3. Characterization of the UL9– pyruvate fusion constructs. (A) The transient transfection –immunoblot analysis of the fusion constructs using
anti-pyruvate kinase rabbit antiserum. The pyruvate kinase fusions are indicated on the top and the positions of the molecular weight markers are
shown on the left. N33-PK– C107 protein migrated as a shorter protein than the N98-PK since the PK cassette used in the N33-PK– C107 fusion
was smaller than that in N98-PK (see Materials and Methods). (B– E) The representative immunofluorescence data. Vero cells were transfected
with the VP16 plasmid alone (B) or cotransfected with the plasmids expressing VP16 and N98-PK (C), N535-PK (D), or N33-PK –C107 (E). The
transfected cells were fixed and stained with the anti-pyruvate kinase rabbit antiserum and rhodamine-conjugated anti-rabbit antiserum. Similar
staining patterns were obtained when the transfected cells were stained with 17B monoclonal antibody. N33-PK, N196-PK, N292-PK, and N660-PK
exhibited staining patterns similar to those seen in C and D. N33-PK–C107(D800-803) exhibited cytoplasmic staining using 17B, anti-PK, or anti-
UL9 rabbit antisera.
presence of the N-terminal 33 amino acids in this construct 4C shows the background staining of untransfected cells.
As is shown in Figs. 4D and 4E, UL9 and D13-536raises the possibility that the C-terminal 107 amino acids
may function in conjunction with the N-terminal 33 amino showed nuclear staining. On the other hand, D800-803
exhibited predominantly cytoplasmic staining (Fig. 4F).acids to form a single signal for nuclear localization; how-
ever, we consider this possibility unlikely because mutants Taken together, the phenotypes of D800-803, D800-851,
and N33-PK – C107(D800-803) suggest that the NLS ofD1-35 and D1-534 localized to the nucleus quite efficiently.
Sequence analysis of the C-terminal 107 amino acids UL9 maps within the C-terminal 107 amino acids of UL9.
A fusion construct containing amino acids 790 –804 ofof UL9 indicates the presence of a 12-amino-acid region
(793-K R E F A G A R F K L R) (Fig. 4A) which is very UL9 fused at the N-terminus of pyruvate kinase, nl-PK,
was not detected by immunoblot or IFA (data not shown)similar to the bipartite NLS consensus sequence [(K/R)
(K/R) (X)n (K/R)3/5] (Dingwall and Laskey, 1991) and is and thus is presumably unstable. Therefore a direct dem-
onstration that the amino acids 793– 804 may constituteconserved among the known homologs from other alpha-
herpesviruses (Fig. 4A). We tested the D800-803 muta- the NLS of UL9 was not possible.
The 17B monoclonal antibody was also used to studytion (which substitutes the right arm of the NLS-like motif
with an alanine residue) in the context of the N33-PK– the subnuclear localization of UL9 in infected cells. To
determine if UL9 colocalizes with ICP8 in replicationC107 construct which was shown above to localize to
the nucleus. This protein, N33-PK– C107(D800-803) ex- compartments, Vero cells were infected with HSV-1
strain KOS and analyzed by IFA. As shown in Figs. 5Ahibited predominantly cytoplasmic staining by IFA and
expressed a protein similar in size to N33-PK – C107 de- and 5B, UL9 and ICP8 were found in a staining pattern
which resembles replication compartments. Both pro-tected by immunoblot analysis (data not shown), sug-
gesting that the NLS-like motif in UL9 may be essential teins colocalize as shown in the merged image (Fig. 5C).
These results confirm the observations made previouslyfor nuclear localization.
We also constructed a deletion construct lacking resi- that UL9 is present in replication compartments which
are the sites of viral replication (Olivo et al., 1989).dues 800 – 803 in the context of the full-length UL9 and
determined the intracellular localization using IFA. Figure It has been proposed that prereplicative sites (ICP8-
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FIG. 4. Mutations designed to alter the putative NLS-like motif in C-terminal 107 region of UL9. (A) Alignment of the amino acid sequence 790–
814 of HSV-1 UL9 protein and the corresponding sequences from equine herpes virus-1 gene 53 and varicella zoster virus gene 51 proteins. The
12-amino-acid sequence constituting the putative NLS of UL9 is underlined. (B) The wild-type version of amino acids 793–804 representing the
putative NLS domain of UL9 is shown on the top line. Mutations in the putative NLS are shown on the next two lines. Deletions D800-803 and
D800-851 were studied in the context of the full-length UL9. D800-803 mutation was also tested in the context of N33-PK –C107 as described in
the text. (C –F) Intracellular localization of the wild-type and mutant forms of UL9. Vero cells were transfected with VP16 plasmid alone (C) or
cotransfected with VP16 and UL9 (D), D13-536 (E), or D800-803 (F). The transfected cells were fixed and incubated with anti-UL9 rabbit antiserum
followed by incubations with biotinylated horse anti-rabbit antibody and fluorescein-conjugated avidin.
stained structures seen in the presence of HSV-1 poly- (Lukonis and Weller, 1996). For instance, KT3 epitope-
tagged UL52 exhibits a complete colocalization with ICP8merase inhibitors) are intermediates in the assembly of
the viral replication apparatus leading to the formation in prereplicative sites (Figs. 5G– 5I). Interestingly, UL9
exhibited a granular staining pattern throughout the nu-of replication compartments. Viruses individually mu-
tated in essential replication proteins have been used to cleus (Fig. 5E), and the colocalization of UL9 and ICP8
is not complete (see below) (Fig. 5F). To confirm thatstudy the requirements for prereplicative site formation
(using ICP8 staining as a marker) (Liptak et al., 1996; the UL9 staining pattern shown in Fig. 5E is not due to
nonspecific staining by the 17B antibody, Vero cells wereLukonis and Weller, 1996). Cells infected with viruses
bearing mutations in UL5, UL8, UL9, or UL52 contain infected with hr94, a virus that does not express UL9,
and processed for IFA. Although ICP8 was reported toICP8 in a diffuse staining pattern. However, in the pres-
ence of HSV-1 polymerase inhibitors, phosphonoacetic exhibit a diffuse staining pattern in hr94-infected cells
(Liptak et al., 1996), in our hands the staining of ICP8 inacid (PAA) or acyclovir, cells infected with these mutants
contain ICP8 in prereplicative sites. Liptak et al. pre- these cells is somewhat granular overlaying a back-
ground of diffuse staining (Fig. 5J). More importantly, UL9sented a model proposing an ordered assembly of repli-
cation proteins leading to prereplicative site formation in was not detected with 17B in Vero cells infected with
hr94 (Fig. 5K).which the helicase – primase (UL5, UL8, and UL52), the
single-stranded DNA binding protein (ICP8), and the ori- The results shown in Figs. 5D – 5F indicate that colo-
calization of UL9 and ICP8 is not complete. Thus ourgin binding protein (UL9) assemble together (Liptak et
al., 1996). One prediction of the ordered assembly model observation that UL9 does not strongly colocalize with
ICP8 in PAA-treated cells may make the ordered assem-of Liptak et al. is that UL9 should colocalize with ICP8
in prereplicative sites (Liptak et al., 1996). bly model (for replication compartment formation) less
attractive. Two other recent observations are relevant inWe examined the localization of UL9 in cells infected
with HSV-1 virus under conditions that block viral replica- this regard. Maul et al. demonstrated that HSV-1 DNA
localizes and replicates adjacent to domains in the nu-tion. Vero cells were infected with the HSV-1 virus in the
presence of PAA and processed for IFA. As shown in cleus called ND10s, nuclear domain 10 (Maul et al.,
1996). ND10s are discrete nuclear-matrix-bound struc-Fig. 5D, ICP8 localizes to numerous punctate structures
called prereplicative sites (de Bruyn Kops and Knipe, tures which are present in the nuclei of most cells and
whose function is currently not known (Maul et al., 1995).1988; Quinlan et al., 1984). The members of the HSV-1
helicase– primase complex (UL5, UL8, and UL52) show Maul et al. further observed that in some HSV-1-infected
cells, ICP8-positive punctate structures, presumably pre-complete colocalization with ICP8 in prereplicative sites
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FIG. 5. Double immunofluorescence labeling of UL9 or UL52 and ICP8 in HSV-1 replication compartments and prereplicative sites. Vero cells
were infected with KOS (A– F) or hr94 virus (J – L) and processed for confocal microscopy. ICP8 was stained with the 3-83 rabbit antiserum and
Texas red-conjugated anti-rabbit antiserum (A, D, G, and J). UL9 was stained with the 17B monoclonal antibody and fluorescein-conjugated anti-
mouse antibody (B, E, and K). (G– I) Vero cells cotransfected with plasmids expressing UL5, UL8, and KT3 epitope-tagged UL52 and superinfected
with a UL52-null virus (hr114) (Lukonis and Weller, 1996). These cells were stained with KT3 ascites and 3-83 antiserum (G– I). (C, F, I, and L) The
merged image of the UL9 or UL52 and the ICP8 staining pattern. (D –I) Vero cells infected in the presence of viral replication inhibitor, phosphonoacetic
acid at 400 mg/ml.
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structures in herpes virus-infected cells requires a viral DNA bindingreplicative sites, were detected, but are not found in as-
protein. Cell 55, 857–868.sociation with ND10s or viral DNA (Maul et al., 1996).
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